ProCE Banner Activity

CE / CME

Addressing the Challenges of Ovarian Cancer

Interactive Video Lecture

Advanced and recurrent ovarian cancer is associated with poor prognosis, and most women with this disease are diagnosed at an advanced stage. In addition, a high rate of recurrence and diminished effectiveness of chemotherapy with each round of treatment helps make ovarian cancer the fifth leading cause of cancer death in women. The discovery of BRCA mutations and other homologous recombination repair deficiencies, and the subsequent approval of poly (ADP-ribose) polymerase (PARP) inhibition for ovarian cancer has changed the treatment paradigm for this disease, with emerging data, guideline updates, new global approvals, and expanded indications occurring frequently. This activity provides expert advice on how to recognize genetic factors that impact patient outcomes, incorporate PARP inhibitor therapy into clinical practice, and manage adverse events related to therapy for optimal treatment outcomes in patients with advanced ovarian cancer.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit
Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: January 31, 2022

Expiration: January 30, 2023

Begin Activity

Share

Faculty

Kimberly J. Halla

Kimberly J. Halla, MSN, FNP-C

Family Nurse Practitioner
Arizona Oncology
Phoenix, Arizona

Acknowledgement

This program was cosupported by educational grants from Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

This activity is supported by educational grants from Merck & Co., Inc and Novartis Pharmaceuticals Corporation.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify factors that can impact optimal management of patients with ovarian cancer

  • Summarize evolving evidence for novel and emerging treatments in ovarian cancer

  • Apply strategies to manage toxicities of novel therapies for ovarian cancer

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Ms Halla: consulting: GlaxoSmithKline, Merck, Seagen.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

CME Info

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: January 31, 2022
Expiration date: January 30, 2023

Format

Interactive video lecture

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 30, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.